Prescribe with Confidence. Your Patients are Covered.

Expanding Commercial Coverage

A majority of patients with commercial insurance have formulary coverage for Taltz

Taltz will replace Cosentyx®(secukinumab) on the OptumRx National Formulary1

Taltz is now covered on the OptumRx Commercial formularies with the status of preferred IL-17A antagonist across all indications.1,†

There are four national formularies:

  • OptumRx Select
  • OptumRx Select with Focused UM
  • OptumRx Premium
  • OptumRx Premium Comprehensive

Taltz is now designated a Tier 3 drug.

Additional Formulary Plan Information

The information in this communication is subject to change without notice.

The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of Lilly USA, LLC.

The formulary information does not include generic medications in this therapeutic class.

This list may not be an exhaustive list of all plans in your area and the coverage of other plans in your area may vary.

Employers and employer groups may also offer additional benefit designs which may be different than described.

Lilly USA, LLC does not endorse any particular plan. Other product and company names mentioned herein are the trademarks of their respective owners.

The formulary information in this document is for select products that share an approved indication with Taltz® (ixekizumab).Inclusion of a product in this information does not establish clinical comparability of the products for any or all indications and should not be seen as making any claim regarding efficacy or safety.

UM=utilization management

†Effective January 1, 2020


Taltz is indicated for your adult patients with active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).
Taltz is also indicated for your adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.


Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.


Taltz Clear Access Program

But national coverage may not translate into individual patient access. The Taltz Clear Access Program can ensure the treatment choice stays between you and your patient.

Access regardless of treatment history or formulary requirements for as little as:

  • $5 per month for patients with coverage
  • $25 per month for patients without coverage

Up to 3 years of access,§ even if insurance continues to deny coverage

Taltz is also authorized to ship within 2 business days to ensure a quick treatment start.

*Terms and Conditions: Offer good for up to 36 months from patient qualification into the program or until 12/31/2023, whichever comes first, provided patient continues to meet program terms and conditions. Patients must first use their card by 12/31/2020. Patient must have coverage for Taltz with their commercial drug insurance to pay as little as $5 monthly for a 28-day supply of Taltz, subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $16,000 maximum annual cap. Patient must have commercial drug insurance and a prescription consistent with FDA approved product labeling to pay as little as $25 monthly for a 28-day supply of Taltz, subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges. Continued participation in the $25 program requires submission of a prior authorization (PA) before the 2nd month fill and, if coverage is denied, an appeal must be submitted prior to 5th month fill. A new PA and appeal or medical exception (ME) must be submitted every 12 months to verify coverage status and potential eligibility for the $5 program. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

Other product/company names are the property of their respective owner.

§Contingent upon a patient scheduling a delivery with a specialty pharmacy.

ǁConstitutes that a prior authorization has been submitted.

Shipment can be authorized within 2 business days of submitting a prescription to either a participating specialty pharmacy or Taltz Together™ and commercial insurance is verified; patient enrolls in the Taltz Savings Card program and schedules shipment.

Network of Specialty Pharmacies


Access Taltz through a specialty pharmacy that is convenient for patients

Support 25-5

Choose a specialty pharmacy that fits prescription process needs

*Government beneficiaries excluded. Terms and conditions apply. See full details here.

Taltz Specialty Pharmacy Network Partners

You can start the enrollment process for your patients using one of the Taltz contracted specialty pharmacies or through Taltz Together.

If using a specialty pharmacy, first make sure it is on the list of Taltz contracted specialty pharmacies*. Many specialty pharmacies offer enrollment forms on their website. Submit the completed specialty pharmacy enrollment form or the Taltz enrollment form to one of the contracted specialty pharmacies. If the preferred specialty pharmacy is not included in the Taltz network, submit the enrollment form to Taltz Together for assistance. If you have questions, your Taltz sales representative will be able to assist you.

*To access the list of contracted specialty pharmacies in Puerto Rico, please contact your local sales representative.


Taltz together logo

Taltz Together is here to provide the resources and support your patients need. For assistance, call 1-844-TALTZ-NOW (1-844-825-8966) or enroll your patients in Taltz Together by completing the Dermatology Enrollment Form or Rheumatology Enrollment Form.

Offerings include:

Taltz support insurance

Insurance Investigation

  • Help with preliminary insurance investigation and specialty pharmacy identification

Support injection training

Injection Training

  • Free of charge to patients and their families
  • Patients can choose either in-person or telephone training
  • Injection training videos available here

Ongoing support

Ongoing Support

  • A personal patient resource to help answer questions or concerns
  • Help is available Monday-Friday from 8 AM to 10 PM ET

Support field reimbursement

Field Reimbursement Support

The Field Reimbursement Manager is an experienced access professional who can help your patients navigate the complex access and reimbursement environment

The managers are

  • Knowledgeable: understand Taltz Together services, access challenges, and affordability options
  • Connected: integrated with the Taltz Together call center and understand the Taltz contracted specialty pharmacy network
  • Patient Focused: committed to providing information to support patient access to Taltz

Support sharps

Sharps Disposal Support

Allows patients to safely dispose of Taltz devices. Once the container is full, your patients can mail it back and contact Taltz Together to receive another one


For more information about Lilly’s privacy practice, please view the Privacy Statement.

Assuring access so your patients* can confidently get Taltz

*Governmental beneficiaries excluded, subject to terms and conditions.

References: 1. Data on File. Lilly USA, LLC. DOF-IX-US-0187.

Indications and Important Safety Information

Taltz is indicated for your adult patients with active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).

Taltz is also indicated for your adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Important Safety Information
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Taltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis and ankylosing spondylitis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz 80 mg Q2W group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis and in the Taltz Q4W group in ankylosing spondylitis trials (Crohn’s disease 1.0% [2 patients], ulcerative colitis 0.5% [1 patient]) than in the placebo group (Crohn’s disease 0.5% [1 patient], ulcerative colitis 0%). In the ankylosing spondylitis trials, serious events occurred in 1 patient in the Taltz group and 1 patient in the placebo group.

Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.